Published in:
Volume 7 / Year 2018 / Issue 1

EU Member States have tools to reduce costs of bestseller biologicals but can they use them?

Page: 5-7

Abstract: Major cost savings are achievable in pharmacotherapy in the European Union since biosimilars to most best-selling biological medicinal products have been licensed. Unfortunately, the window of opportunity may be… Read More »

Go Back Print